Your browser doesn't support javascript.
loading
Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia.
Dalmasso, B; Pastorino, L; Nathan, V; Shah, N N; Palmer, J M; Howlie, M; Johansson, P A; Freedman, N D; Carter, B D; Beane-Freeman, L; Hicks, B; Molven, A; Helgadottir, H; Sankar, A; Tsao, H; Stratigos, A J; Helsing, P; Van Doorn, R; Gruis, N A; Visser, M; Wadt, K A W; Mann, G; Holland, E A; Nagore, E; Potrony, M; Puig, S; Menin, C; Peris, K; Fargnoli, M C; Calista, D; Soufir, N; Harland, M; Bishop, T; Kanetsky, P A; Elder, D E; Andreotti, V; Vanni, I; Bruno, W; Höiom, V; Tucker, M A; Yang, X R; Andresen, P A; Adams, D J; Landi, M T; Hayward, N K; Goldstein, A M; Ghiorzo, P.
Affiliation
  • Dalmasso B; IRCCS Ospedale Policlinico San Martino, Genetics of Rare Cancers, Genoa, Italy. brunasamia.dalmasso@dimi.unige.it.
  • Pastorino L; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy. brunasamia.dalmasso@dimi.unige.it.
  • Nathan V; IRCCS Ospedale Policlinico San Martino, Genetics of Rare Cancers, Genoa, Italy.
  • Shah NN; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
  • Palmer JM; Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Howlie M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Johansson PA; Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Freedman ND; Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Carter BD; Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Beane-Freeman L; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Hicks B; American Cancer Society, Atlanta, GA, USA.
  • Molven A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Helgadottir H; Cancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Sankar A; Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Tsao H; Department of Pathology, Haukeland University Hospital, Bergen, Norway.
  • Stratigos AJ; Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden.
  • Helsing P; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
  • Van Doorn R; Wellman Center for Photomedicine, Department of Dermatology, MGH Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
  • Gruis NA; First Department of Dermatology-Venereology, Andreas Sygros Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Visser M; Department of Dermatology, Oslo University Hospital, Oslo, Norway.
  • Wadt KAW; Department Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Mann G; Department Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Holland EA; Department Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Nagore E; Department of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark.
  • Potrony M; Centre for Cancer Research, Westmead Institute for Medical Research, University of Sydney, Westmead, Australia.
  • Puig S; Centre for Cancer Research, Westmead Institute for Medical Research, University of Sydney, Westmead, Australia.
  • Menin C; Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain.
  • Peris K; Biochemistry and Molecular Genetics Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
  • Fargnoli MC; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
  • Calista D; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
  • Soufir N; Dermatology Department, Melanoma Unit, HospitalClínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
  • Harland M; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Bishop T; Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.
  • Kanetsky PA; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
  • Elder DE; Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Andreotti V; Dermatology Unit, Maurizio Bufalini Hospital, Cesena, Italy.
  • Vanni I; Dépatement de Génétique Moléculaire, Hôpital Bichat-Claude Bernard, Paris, France.
  • Bruno W; Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • Höiom V; Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • Tucker MA; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Yang XR; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Andresen PA; IRCCS Ospedale Policlinico San Martino, Genetics of Rare Cancers, Genoa, Italy.
  • Adams DJ; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
  • Landi MT; IRCCS Ospedale Policlinico San Martino, Genetics of Rare Cancers, Genoa, Italy.
  • Hayward NK; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
  • Goldstein AM; IRCCS Ospedale Policlinico San Martino, Genetics of Rare Cancers, Genoa, Italy.
  • Ghiorzo P; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
Genet Med ; 23(11): 2087-2095, 2021 11.
Article in En | MEDLINE | ID: mdl-34262154
ABSTRACT

PURPOSE:

Ataxia-Telangiectasia Mutated (ATM) has been implicated in the risk of several cancers, but establishing a causal relationship is often challenging. Although ATM single-nucleotide polymorphisms have been linked to melanoma, few functional alleles have been identified. Therefore, ATM impact on melanoma predisposition is unclear.

METHODS:

From 22 American, Australian, and European sites, we collected 2,104 familial, multiple primary (MPM), and sporadic melanoma cases who underwent ATM genotyping via panel, exome, or genome sequencing, and compared the allele frequency (AF) of selected ATM variants classified as loss-of-function (LOF) and variants of uncertain significance (VUS) between this cohort and the gnomAD non-Finnish European (NFE) data set.

RESULTS:

LOF variants were more represented in our study cohort than in gnomAD NFE, both in all (AF = 0.005 and 0.002, OR = 2.6, 95% CI = 1.56-4.11, p < 0.01), and familial + MPM cases (AF = 0.0054 and 0.002, OR = 2.97, p < 0.01). Similarly, VUS were enriched in all (AF = 0.046 and 0.033, OR = 1.41, 95% CI = 1.6-5.09, p < 0.01) and familial + MPM cases (AF = 0.053 and 0.033, OR = 1.63, p < 0.01). In a case-control comparison of two centers that provided 1,446 controls, LOF and VUS were enriched in familial + MPM cases (p = 0.027, p = 0.018).

CONCLUSION:

This study, describing the largest multicenter melanoma cohort investigated for ATM germline variants, supports the role of ATM as a melanoma predisposition gene, with LOF variants suggesting a moderate-risk.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ataxia Telangiectasia / Melanoma Type of study: Clinical_trials Limits: Humans Country/Region as subject: Oceania Language: En Journal: Genet Med Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ataxia Telangiectasia / Melanoma Type of study: Clinical_trials Limits: Humans Country/Region as subject: Oceania Language: En Journal: Genet Med Year: 2021 Document type: Article